WO2020032885A2 - Compositions capsule dans capsule d'étéxilate de dabigatran - Google Patents

Compositions capsule dans capsule d'étéxilate de dabigatran Download PDF

Info

Publication number
WO2020032885A2
WO2020032885A2 PCT/TR2019/050292 TR2019050292W WO2020032885A2 WO 2020032885 A2 WO2020032885 A2 WO 2020032885A2 TR 2019050292 W TR2019050292 W TR 2019050292W WO 2020032885 A2 WO2020032885 A2 WO 2020032885A2
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
acid
formulation
poly
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050292
Other languages
English (en)
Other versions
WO2020032885A3 (fr
Inventor
Arzu PALANTOKEN
Yildiz Gulkok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2018/06309A external-priority patent/TR201806309A2/tr
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP19848668.0A priority Critical patent/EP3787624A4/fr
Publication of WO2020032885A2 publication Critical patent/WO2020032885A2/fr
Publication of WO2020032885A3 publication Critical patent/WO2020032885A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to capsule-in-capsule compositions comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and at least one organic acid, characterized in that one of the capsules comprises at least one coating.
  • Dabigatran is a potent, reversible, univalent direct thrombin inhibitor. Dabigatran was first disclosed in WO98/37075, which claimed compounds with a thrombin-inhibiting effect and the effect of prolonging the thrombin time, under the name 1-methyl-2-[N-[4-(N-n- hexyloxycarbonylamidino) phenyl] aminomethyl] benzimidazol-5-ylcarboxylic acid-N-(2- pyridyl)-N-(2 ethoxycarbonylethyl)amides.
  • Dabigatran etexilate a novel direct thrombin inhibitor, is a prodrug of dabigatran and is a non-peptide thrombin inhibitor.
  • the structural formula is:
  • Dabigatran is currently available as dabigatran etexilate mesylate, under the trade name Pradaxa from Boehringer Ingelheim is used for the reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
  • the solubility of dabigatran etexilate mesylate in water is 1.8 mg/mL and dependent on the pH value.
  • EP1658056B1 suggests a tablet formulation containing dabigatran etexilate and an organic acid with a solubility in water of > 1 g / 250 ml at 20°C.
  • EP2740471 B1 discloses a pharmaceutical composition contains the following main components: a core material comprising an inorganic acid layer, an active substance layer and an insulating layer between inorganic acid layer and active substance layer.
  • EP2588090A2 discloses a process for the preparation of an oral dosage comprising a spherical core coated with tartaric acid, a isolating layer on the coated tartaric acid layer and a layer comprising dabigatran etexilate on the isolating layer.
  • WO2015145462A1 discloses a pharmaceutical composition comprising a first component in the form of tablet comprising dabigatran and a second component in the form of capsule comprising organic acid.
  • the main object of the present invention is to provide capsule-in-capsule compositions comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and at least one organic acid in a unit dosage form with desired stability and effective dissolution profile.
  • Another object of the present invention is to provide an easy and cost-effective process for the preparation of the said pharmaceutical composition.
  • said pharmaceutical composition comprises a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and at least one organic acid, wherein the capsule-in- capsule composition is comprising a first capsule and a second capsule which is located within the first capsule.
  • the term“unit dosage form” refers to nested capsule technology which is comprising a first capsule and a second capsule, the second capsule being located within the body of the first capsule.
  • the first capsule comprises a first formulation which may be a direct thrombin inhibitor or an organic acid.
  • the second capsule comprises a second formulation which may be a direct thrombin inhibitor or an organic acid.
  • dabigatran etexilate free base refers to dabigatran etexilate which is free from other forms of the active moiety, especially acid addition salts.
  • the first capsule is comprising a first formulation
  • the second capsule is comprising a second formulation
  • the present invention provides stable composition in a single dosage unit. Especially, coating the second capsule with at least one coating has surprisingly provided the stability of the composition. To prepare the coating step at capsule- in-capsule composition is easier and this method eliminates both incompatibility and stability problems encountered in the prior art.
  • the first formulation and the second formulation are in the form of mini tablets or granules or pellets or powder or beads or capsules or mixtures thereof.
  • the first formulation is comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or an organic acid.
  • the second formulation is comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or an organic acid.
  • the pharmaceutical composition in a dosage unit form comprises a first capsule and a second capsule which is located within the first capsule, wherein the first capsule comprising a first formulation held between the first and second capsule and comprising a second formulation held in the second capsule, and wherein the first formulation or the second formulation comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or at least one organic acid.
  • a capsule-in-capsule composition comprises,
  • the first capsule comprising a first formulation held between the first and second capsule comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or at least one organic acid
  • the second capsule comprising a second formulation comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or at least one organic acid
  • the second capsule further comprising at least one coating.
  • the direct thrombin inhibitor is dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.
  • the raw material of the capsule is hydroxypropyl methylcellulose (HPMC) or gelatin which can be alkali-treated gelatin, acid-treated gelatin, or chemically modified gelatin.
  • HPMC hydroxypropyl methylcellulose
  • gelatin which can be alkali-treated gelatin, acid-treated gelatin, or chemically modified gelatin.
  • the capsule material may further include agar, starch, alginic acid, guar gum, plasticizer and mixtures thereof.
  • HPMC based capsules has retardant effects on the rate of dissolution compared to gelatin based capsules.
  • Gelatin based capsules can be more preferable than HPMC based capsules when using acid in the pharmaceutical composition.
  • the capsule filled with the organic acid, or the coated organic acid, or the powder mixture containing organic acid is made of gelatin or HPMC, preferably gelatin.
  • the capsule filled with dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof is made of gelatin or HPMC.
  • Hard gelatin capsules contain 13-16% water. Low humidity may cause them to become fragile. However, Dabigatran etexilate is able to maintain its stability against heat and light under hardened conditions, while moisture is degraded.
  • the second capsule can be coated with at least one coating comprising water-soluble polymer.
  • the weight of at least one coating is between 0.5% and 4.0% or between 0.75% and 2.0% in the composition. It is used in such a small proportion provides an advantage in terms of stability without causing any delay in resolution.
  • the second capsule comprises at least one coating which having water-soluble polymer.
  • Suitable water-soluble polymer is selected from hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), hydroxyethylcellulose and derivatives, ethylcellulose and ethyl hydroxyethylcellulose, carboxymethylcellulose (CMC), methyl cellulose (MC), polyvinyl alcohol (PVA), polyethylene glycol (PEG), polyethylene oxide (PEO), poly(ethylene oxide-b-propylene oxide), polyoxyethylene (POE), polyvinylpyrrolidone (PVP), polyethylenimine (PEI), poly(N-vinylpyrrolidone/vinyl acetate), polyvinylpyrollidone PVP K-90, polyacrylic acid and copolymers, poly(vinylamine) hydrochloride, poly(acrylic acid sodium salt), poly(methacrylic acid), poly(methylacrylic acid sodium salt), poly(ethylene/acrylic acid), poly(2-hydroxyethyl methacrylate/methacrylic acid), poly
  • the water-soluble polymer is hydroxypropyl methylcellulose (HPMC) or polyethylene glycol (PEG) or polyvinylpyrrolidone or poly(N-vinylpyrrolidone/vinyl acetate) or polyvinyl alcohol or mixtures thereof.
  • a first formulation in the first capsule comprises dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and a second formulation in the second capsule comprises at least one organic acid. The presence of dabigatran etexilate and at least one organic acid in the indicated capsules helped to achieve the desired dissolution.
  • the capsule-in-capsule composition comprises;
  • the first capsule comprising a first formulation comprising dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof
  • the second capsule comprising a second formulation comprising at least one organic acid wherein the second capsule further comprising at least one coating which having water- soluble polymer.
  • the capsule-in-capsule composition comprises;
  • the first capsule comprising a first formulation comprising at least one organic acid
  • the second capsule comprising a second formulation comprising dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof
  • the second capsule further comprising at least one coating which having water- soluble polymer.
  • Suitable organic acid comprises at least one carboxylic group. It is selected from the group comprising citric acid, tartaric acid, gallic acid, orotic acid, p-coumaric acid, hippuric acid, ferulic acid, vanillic acid, fumaric acid, maleic acid, succinic acid, malic acid, glutamic acid, aspartic acid, oxalic acid, lactic acid, formic acid, acetic acid, propionic acid, caproic acid, benzoic acid, carbonic acid, adipic acid or mixtures thereof.
  • the organic acid is citric acid or tartaric acid or mixtures thereof.
  • the organic acid pellets or the organic acid granules are coated with an isolation solution.
  • the isolation solution is formed of a polymeric or a non-polymeric pharmaceutically acceptable agent or any combination thereof.
  • the organic acid has important role in high bioavailability and solubility of dabigatran etexilate.
  • use of high amount of organic acid may cause incompatibilities in the patient or can limit the amount of drug used in the pharmaceutical preparation due to their intrinsic properties. That reasons should be taken in consideration when determining the amount of the direct thrombin inhibitor and the organic acid in the pharmaceutical composition.
  • the weight ratio of dabigatran etexilate to the organic acid is between 0.6 and 8.0 or between 0.75 and 3.0, between 1.0 and 5.0.
  • the weight ratio of the dabigatran etexilate to the citric acid is between 0.6 and 8.0 or between 0.75 and 3.0, between 1.0 and 5.0.
  • the weight ratio of the dabigatran etexilate to the tartaric acid is between 0.6 and 8.0 or between 0.75 and 3.0, between 1.0 and 5.0.
  • the said composition comprises at least one pharmaceutically acceptable excipient selected from fillers, disintegrants, diluents, dispersing agents, binders, lubricants, glidants, plasticizers, preservatives, sweeteners, flavorings, melting components, coloring agents, solvents, or mixtures thereof.
  • Suitable fillers may include but not limited to lactose, sugar, starches, modified starches, mannitol, calcium sulfate, xylitol, or mixtures thereof.
  • Suitable disintegrants may include but not limited to cross-linked polyvinylpyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, polyacrylate potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • crospovidone cross-linked polyvinylpyrrolidone
  • povidone povidone
  • carboxymethyl cellulose croscarmellose sodium
  • low-substituted hydroxypropyl cellulose pregelatinized starch
  • Suitable diluents may include but not limited to microcrystalline cellulose, mannitol, spray- dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • Suitable dispersing agents may include but not limited to calcium silicate, magnesium aluminum silicate or mixtures thereof.
  • Suitable binders may include but not limited to polyvinylpyrrolidone, carnauba wax, pullulan, glyceryl behenate, polycarbophil, polyvinyl acetate and its copolymers, cellulose acetate phthalate, hydroxypropyl starch, sugars, tragacanth gum, cetostearyl alcohol, acacia mucilage, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, cellulose derivatives such as hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, ethyl cellulose, microcrystalline cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, carrageenan, guar gum, polymethacrylates, methacrylate polymers, collagens, proteins like gelatin, agar, alginate, xant
  • Suitable lubricants may include but not limited to magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito stearate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
  • Suitable glidants may include but not limited to colloidal silicon dioxide, talc, aluminium silicate, silica or mixtures thereof.
  • Suitable plasticizers may include but not limited to polyethylene glycols of different molecular weights, propylene glycol or mixtures thereof.
  • Suitable preservatives may comprise but not limited to methyl paraben and propyl paraben and their salts (such as sodium, potassium), sodium benzoate, citric acid, benzoic acid, butylated hydroxytoluene and butylated hydroxyanisole or mixtures thereof.
  • Suitable sweeteners may include but not limited to aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose and sugar alcohols such as mannitol, sorbitol, xylitol, erythritol or mixtures thereof.
  • Suitable flavorings may include but not limited to menthol, peppermint, cinnamon, chocolate, vanillin and fruit essences such as cherry, orange, strawberry, grape, black currant, raspberry, banana, red fruits, wild berries etc. or mixtures thereof.
  • Suitable melting components are selected from gelucire (stearyl macrogolglyceride), poloxamer (polyoxyethylene-polyoxypropylene block copolymer), polyethylene glycol, povidone, soluplus, cationic methacrylate, copovidone, methacrylic acid copolymers, cellulose acetate phthalate, acetylated monoglyceride, butil pthalybutyl glycolate, dibutyl tartrate, diethyl phthalate, dimethly phthalate, ethyl phthalylethly glycolate, glycerin, propylene glycol, triacetin, triacetin citrate, tripropionin or mixtures thereof.
  • Suitable coloring agents may include but not limited to ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine), iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • D&C Drug & Cosmetic
  • Suitable solvents may include but not limited to ethyl alcohol, 2-propanol, water or mixtures thereof.
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • binder - 1.0 - 30.0% by weight of binder
  • the second formulation comprising - 10.0 - 50.0% by weight of organic acid pellets or coated (isolated) organic acid pellets or powder mixture containing organic acid;
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • binder - 1.0 - 30.0% by weight of binder
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • the first formulation comprising - 10.0 - 50.0% by weight of citric acid or tartaric acid pellets or coated (isolated) citric acid or tartaric acid pellets or powder mixture containing citric acid or tartaric acid, and
  • dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • coating the second capsule of the present invention may be prepared by a process comprising the following steps:
  • compositions of the present invention may be prepared by a process comprising the following steps:
  • compositions of the present invention may be prepared using wet-granulating processes in which a powder is added with a binder and a solvent then granulated, dry-granulating processes such as slugging or compaction and direct compression, or melt-granulating processes in which a powder is mixed with a heat-melting binder and then heat-granulated.
  • These granulating processes may be combined with various granulating processes such as agitating granulation method used with machines such as planetary mixers and screw mixers, high shear granulation method used with machines such as Henschel mixers and super mixers, extrusion granulation method used with machines such as cylindrical, rotary granulator, screw-extruding granulator and pellet-mill granulator, or other processes like, tumbling-granulation method, fluidized-bed granulation method, compression granulation method, crushing granulation method, and spray dry granulation method.
  • the foregoing granulation processes may be used alone and no limitation in usage.
  • the particles may then be milled to achieve the desired particle size.
  • suitable processes for milling the granules include hammer milling, ball milling, fluid-energy milling, roller milling, cutting milling, or other milling processes known in the art.
  • pellets refers to small particles with approximately uniform shapes and sizes produced by an extrusion process.
  • A“small particle” refers to a particle of which diameter, length, height, and width is at most 10 mm (e.g., at most 2, 3, 4, 5, 6, 7, 8, or 9 mm).
  • spherical pellet refers to beads, beadlets, spherical particles, spheroids, or the like that are of round or about round in shape and are generally made by an extrusion and spheronization process.
  • mini tablet refers to small tablets with a diameter equal to or less than 4 mm that are typically filled into a capsule or further compressed into larger tablets. Thickness of this mini tablets equal to or less than 3 mm.
  • the mini tablets have round shape and smooth surface to ease coating process.
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process for the first or second formulation comprising the following steps:
  • step (a) Granulating the blend of step (a);
  • step (b) Drying or cooling the granules obtained in step (b);
  • step (c) optionally adding at least one pharmaceutically acceptable excipient to the granules obtained in step (c) and mixing;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process for the first or second formulation comprising the following steps:
  • step (a) Blending organic acid and optionally at least one pharmaceutically acceptable excipient; b. Granulating the blend of step (a) to form organic acid granules or extruding or spheronizing the blend of step (a) to form organic acid pellets;
  • step (b) or step (c) Filling the organic acid granules or pellets obtained in step (b) or step (c) into the first capsule or the second capsule.
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Granulating the blend of step (i) with water;
  • step (i) Extruding or spheronizing the blend of step (i) to form citric acid pellets or tartaric acid pellets;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps: a. Preparing the first formulation comprising
  • step (i) Extruding or spheronizing the blend of step (i) to form citric acid pellets or tartaric acid pellets;
  • step (i) Granulating the blend of step (i) with water;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process for the first or the second formulation comprising the following steps:
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process for the first or the second formulation comprising the following steps: a. Sieving and mixing organic acid and optionally at least one pharmaceutically acceptable excipient;
  • Example 1 Filling the mini tablets into the first capsule or the second capsule.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Organic acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Organic acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Citric acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Citric acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Organic acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, icrocrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Organic acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed. Preparation of Nested Capsules
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Citric acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed. Preparation of Nested Capsules
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Citric acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed. Preparation of Nested Capsules
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Tartaric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • isolation solution which is selected from Formula 1 to 3.
  • Tartaric acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed. Preparation of Nested Capsules
  • Coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Tartaric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • isolation solution which is selected from Formula 1 to 3.
  • Tartaric acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed. Preparation of Nested Capsules
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1-2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium stearate is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • the present invention provides other solutions by using cyclodextrin or polyvinylpyrrolidone (PVP) or polyethylene glycol (PEG) or mixture thereof for increasing solubility of dabigatran etexilate in these pharmaceutical compositions.
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • binder - 1.0 - 30.0% by weight of binder
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (vi) adding lubricant to the granules obtained in step (vi) and mixing;
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets;
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (i) Extruding or spheronizing the blend of step (i) to form citric acid or tartaric acid pellets;
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • binder - 1.0 - 30.0% by weight of binder
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets;
  • Preparing the second formulation comprising i. Suspending the direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof with a solvent to obtain a first suspension;
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (vi) adding lubricant to the granules obtained in step (vi) and mixing;
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • citric acid or tartaric acid pellets or coated (isolated) citric acid or tartaric acid pellets or powder mixture containing citric acid or tartaric acid and
  • dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps: a. Preparing the first formulation comprising
  • step (i) Extruding or spheronizing the blend of step (i) to form citric acid or tartaric acid pellets;
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (vi) adding magnesium stearate to the granules obtained in step (vi) and mixing.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Organic acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol or water. Cyclodextrin or PVP or PEG is suspended with water. Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol or water at 30-35°C. Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol or water. Cyclodextrin or PVP or PEG is suspended with water. Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol or water at 30-35°C. Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved. Magnesium stearate is added and mixed 1-2 more minutes. The powder mixture is compressed into mini tablets.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, Cyclodextrin or PVP or PEG, Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide, croscarmellose sodium and half of magnesium stearate are sieved and mixed.
  • the mixture is compressed by roller compaction.
  • the compressed mixture (granules) is sieved.
  • Remaining magnesium stearate is added to the sieved granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Example 12
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Organic acid, lactose spray dried, colloidal silicone dioxide and pregelatinized starch are sieved and blended. Magnesium stearate is added and mixed 1-2 more minutes.
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol or water. Cyclodextrin or PVP or PEG is suspended with water. Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol or water at 30-35°C. Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol or water. Cyclodextrin or PVP or PEG is suspended with water. Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol or water at 30-35°C. Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved. Magnesium stearate is added and mixed 1-2 more minutes. The powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • Dabigatran etexilate, Cyclodextrin or PVP or PEG, Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide, croscarmellose sodium and half of magnesium stearate are sieved and mixed.
  • the mixture is compressed by roller compaction.
  • the compressed mixture (granules) is sieved.
  • Remaining magnesium stearate is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule and coating the second capsule with at least one water-soluble polymer.
  • organic acid is selected from a group comprising citric acid, tartaric acid, gallic acid, orotic acid, p-coumaric acid, hippuric acid, ferulic acid, vanillic acid, fumaric acid, maleic acid, succinic acid, malic acid, glutamic acid, aspartic acid, oxalic acid, lactic acid, formic acid, acetic acid, propionic acid, caproic acid, benzoic acid, carbonic acid, adipic acid or mixtures thereof.
  • organic acid is citric acid or tartaric acid or mixture thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions capsule dans capsule comprenant de l'étéxilate de dabigatran sous la forme de la base libre ou sous la forme de sels, de polymorphes, de solvates, d'hydrates ou d'esters pharmaceutiquement acceptables de ces derniers et au moins un acide organique, lesdites compositions étant caractérisées en ce que l'une des capsules comprend au moins un revêtement.
PCT/TR2019/050292 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran Ceased WO2020032885A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19848668.0A EP3787624A4 (fr) 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2018/06309A TR201806309A2 (tr) 2017-05-10 2018-05-04 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR2018/06309 2018-05-04
TR201906582 2019-05-03
TR2019/06582 2019-05-03

Publications (2)

Publication Number Publication Date
WO2020032885A2 true WO2020032885A2 (fr) 2020-02-13
WO2020032885A3 WO2020032885A3 (fr) 2020-09-24

Family

ID=69414341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050292 Ceased WO2020032885A2 (fr) 2018-05-04 2019-05-03 Compositions capsule dans capsule d'étéxilate de dabigatran

Country Status (2)

Country Link
EP (1) EP3787624A4 (fr)
WO (1) WO2020032885A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577067A (zh) * 2021-06-03 2021-11-02 北京福元医药股份有限公司 一种甲磺酸达比加群酯药物制剂
CN120938941A (zh) * 2025-10-17 2025-11-14 杭州高成生物营养技术有限公司 一种酒石酸微丸及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124340A1 (fr) 2012-02-21 2013-08-29 Laboratorios Del Dr. Esteve, S.A. Compositions pharmaceutiques orales de dabigatran étexilate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001272645A1 (en) * 2000-07-20 2002-02-05 Mw Encap Limited Delivery device
EP2588090B2 (fr) * 2010-07-01 2023-11-22 KRKA, tovarna zdravil, d.d., Novo mesto Formes pharmaceutiques posologiques orales comprenant de l'étéxilate de dabigatran et ses sels pharmaceutiquement acceptables
WO2012162492A1 (fr) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Noyau comprimé comprenant des acides organiques pour une composition pharmaceutique
RU2015140610A (ru) * 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
IN2013CH05441A (fr) * 2013-11-26 2015-05-29 Aurobindo Pharma Ltd
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
WO2015155297A1 (fr) * 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et d'antagonistes du récepteur h2
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
WO2016142821A2 (fr) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions contenant un inhibiteur de la thrombine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124340A1 (fr) 2012-02-21 2013-08-29 Laboratorios Del Dr. Esteve, S.A. Compositions pharmaceutiques orales de dabigatran étexilate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577067A (zh) * 2021-06-03 2021-11-02 北京福元医药股份有限公司 一种甲磺酸达比加群酯药物制剂
CN113577067B (zh) * 2021-06-03 2023-08-15 北京福元医药股份有限公司 一种甲磺酸达比加群酯药物制剂
CN120938941A (zh) * 2025-10-17 2025-11-14 杭州高成生物营养技术有限公司 一种酒石酸微丸及其制备方法

Also Published As

Publication number Publication date
WO2020032885A3 (fr) 2020-09-24
EP3787624A2 (fr) 2021-03-10
EP3787624A4 (fr) 2022-03-30

Similar Documents

Publication Publication Date Title
US10406105B2 (en) Pharmaceutical formulation for the production of rapidly disintegrating tablets
US20170333424A1 (en) Amorphous Vortioxetine Hydrobromide
JP2012184267A (ja) 安定性の向上した固形製剤およびその製造方法
KR102082775B1 (ko) 수용해도 및 생체이용율이 개선된 조성물
JP2013532651A (ja) シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
WO2015145462A1 (fr) Compositions pharmaceutiques de dabigatran
WO2023195955A1 (fr) Comprimé revêtu d'un film comprenant du sélexi̇pag et son procédé de préparation
CA2934586A1 (fr) Composition pharmaceutique
EP2012754B1 (fr) Formulation pharmaceutique à libération rapide orale pour esomeprazole
WO2020032885A2 (fr) Compositions capsule dans capsule d'étéxilate de dabigatran
WO2014060561A1 (fr) Formulations pharmaceutiques orales contenant du dabigatran
WO2023195957A1 (fr) Comprimé pelliculé comprenant du selexi̇pag traité par granulation humide
TWI871668B (zh) 醫藥調配物
CN101854921B (zh) 用于口服施用ppi的药物制剂
KR102707060B1 (ko) 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
WO2019004980A2 (fr) Compositions pharmaceutiques orales solides d'étéxilate de dabigatran
AU2018293361B2 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
US20080182908A1 (en) Pharmaceutical compositions comprising memantine
KR101428149B1 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
WO2021150187A1 (fr) Capsule-dans-capsule à base d'étéxilate de dabigatran
WO2020209813A1 (fr) Formulation de capsule d'étéxilate de dabigatran
EP4504195A1 (fr) Comprimé pelliculé comprenant du selexipag traité par granulation humide
WO2023195956A1 (fr) Comprimé revêtu d'un film comprenant du sélexi̇pag et au moins une charge
WO2025212071A1 (fr) Dispersion solide d'enzalutamide
EP3731823A1 (fr) Préparation pharmaceutique pour administration par voie orale comportant de l'étexilate de dabigatran

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19848668

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019848668

Country of ref document: EP

Effective date: 20201204